Beyond Genomics and AstraZeneca to apply Systems Biology to Toxicology Study
Waltham, MA - Beyond genomics, Inc. announced that it has entered into a pilot agreement with AstraZeneca to apply its systems biology expertise to the area of predictive toxicology. Beyond Genomics (BG) will utilize its proprietary Systems Biology platforms and BioSystematics(TM) informatics tools to analyze and integrate transcript, protein, and metabolite data in a study designed to discover biomarkers of drug-induced toxicity. Financial terms were not disclosed.
"By partnering with AstraZeneca, a global leader in pharmaceutical research and development, in the important area of toxicology, we can demonstrate that BG's Systems Biology approach delivers critical knowledge that can be applied to reduce development costs and advance drugs with improved safety profiles," Muz Mansuri, Executive Chairman of Beyond Genomics explained.
BG's proprietary Systems Biology platforms generate BioSystem Markers(TM), unique molecular "signatures" indicative of various biological states such as health, disease, therapeutic response, or, in the case of predictive toxicology, early indicators of a toxic response. BioSystem Markers(TM) are discovered by using relevant human or animal samples and are comprised of one or more biomolecular class (e.g., transcript, protein, and metabolite) that, when evaluated together, are uniquely characteristic of a biological state.
Other news from the department business & finance
